Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04882306
Other study ID # PROTOCOL-P2-054
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date February 16, 2022
Est. completion date October 31, 2022

Study information

Verified date May 2022
Source Micrima, Ltd.
Contact Caroline Gillett
Phone 0117 251 9032
Email caroline.gillett@micrima.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The MARIA® breast imaging system is a CE-marked radiofrequency (RF) medical imaging device. The system employs an electromagnetic imaging technique that exploits the dielectric contrast between normal and cancerous tissues. It is the intention that MARIA® will be able to offer a breast density classifier to clinician's but for this project to be successful, data is required. This study will collect the data required for the classifier to be developed.


Recruitment information / eligibility

Status Recruiting
Enrollment 800
Est. completion date October 31, 2022
Est. primary completion date August 15, 2022
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - To be eligible to participate in this study, a subject must meet all the following criteria: - Attending a symptomatic or assessment breast clinic at the study site - Female sex - 18 years or older - Able to provide informed consent - Not in any identified, vulnerable group Exclusion Criteria: - A potential subject who meets any of the following criteria will be excluded from participation in this study: - Unable to mount MARIA® patient bed - Unable to lie in the prone position for a period of up to 15 minutes - Patients who have undergone biopsy less than 5 days before the MARIA® scan - Patients with implanted electronics - Patients with breast implants - Patients with nipple piercings (unless they are removed prior to the MARIA® scan) - Breast sizes too small or too large to be suitable for the array Participants recruited the same day are not subject to any additional screening criteria other than that described above. However, participants being recruited and consenting to the use of previously- taken mammography will need to provide information on key points in order to assess the eligibility of their mammograms for use. This will include information on: - Whether they have initiated or discontinued use of a hormonal contraceptive since their last mammogram - Whether they have initiated or discontinued use of hormone replacement therapy since their last mammogram - Whether they believe that they have had a change in menopausal status since their last mammogram Participants who answer yes to any of the above will not be eligible for participation.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Bilateral MARIA scan
After consent has been given, the participant's breast will be fitted by the operator using a clear plastic cup to determine their corresponding MARIA® cup insert size. Once this has been determined, participants will be required to lie prone with their breast pendent through an aperture in the MARIA® patient bed. The cup insert will contain a layer of coupling fluid. The hemispherical cup inserts, and array are brought into contact with the breast. Depending on the patient's breast size, one or more cup inserts may be placed in the array to ensure a good but non-compressing fit between the breast and the system interface. The scan sequence will then be performed, this takes a couple of minutes.

Locations

Country Name City State
United Kingdom North Devon Breast Screening Service- In Health Exeter

Sponsors (1)

Lead Sponsor Collaborator
Micrima, Ltd.

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary The creation of the required dataset to develop the breast density classification algorithm Dataset of information containing ground truth breast density from mammogram 12 months
Primary The creation of that algorithm Using the current breast density algorithm developed for MARIA to analyse the MARIA images and compare that to the mammographic ground truth 12 months
Primary The assessment of the performance of that algorithm to measure breast density when compared to the ground truth of the Boyd score Analyse the values obtained from both the MARIA algorithm and the mammographic ground truth, and look for correlation using the Boyd percentage score of breast density. 12 months
Secondary Understand participant acceptability of the MARIA® scan Using a specially-designed patient questionnaire, analyse feedback on the MARIA scan experience using a scale from Very acceptable-Acceptable-Neither acceptable or unacceptable-Unacceptable-Very unacceptable. 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A